89
Participants
Start Date
March 31, 2008
Primary Completion Date
April 30, 2014
Study Completion Date
June 30, 2015
Gemcitabine,
Gemcitabine will be administered intravenously at a dose of 1000 mg/m2 on Days 1, 8 and 15 of cycle. One treatment cycle is 28 days.
Cisplatin
Cisplatin will be administered intravenously at a dose of 70 mg/m2 per institutional standards on Day 1 of each cycle.
Cetuximab
Cetuximab will be administered intravenously at a dose of 500 mg/m2 on Days 1 and 15 of each cycle. One treatment cycle is 28 days.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore
Vanderbilt-Ingram Cancer Center, Nashville
University of Michigan, Ann Arbor
Wayne State University/Karmanos Cancer Institute, Detroit
Robert H. Lurie Comprehensive Cancer Center, Center of Northwestern University, Chicago
University of Utah Huntsman Cancer Institute, Salt Lake City
Kenneth J. Norris Jr. Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles
City of Hope Cancer Center, Duarte
Stanford University, Stanford
University of Washington, Seattle
Boston Medical Center, Boston
Lahey Clinic, Burlington
Roswell Park Cancer Institute, Buffalo
University of Texas MD Anderson Cancer Center, Houston
Collaborators (1)
National Comprehensive Cancer Network
NETWORK
Bristol-Myers Squibb
INDUSTRY
Eli Lilly and Company
INDUSTRY
University of Michigan Rogel Cancer Center
OTHER